Blood Pressure Levels, Cardiovascular Events, and Renal Outcomes in Chronic Kidney Disease Without Antihypertensive Therapy: A Nationwide Population-Based Cohort Study

Author:

Wu Shujing12,Li Mian12ORCID,Lu Jieli12,Tang Xulei3,Wang Guixia4,Zheng Ruizhi12ORCID,Niu Jingya125,Chen Li6,Huo Yanan7,Xu Min12,Wang Tiange12ORCID,Zhao Zhiyun12ORCID,Wang Shuangyuan12,Lin Hong12,Qin Guijun8,Yan Li9,Wan Qin10,Chen Lulu11,Shi Lixin12,Hu Ruying13,Su Qing14,Yu Xuefeng15,Qin Yingfen16,Chen Gang17ORCID,Gao Zhengnan18,Shen Feixia19,Luo Zuojie16,Chen Yuhong12,Zhang Yinfei20,Liu Chao21,Wang Youmin22,Wu Shengli23,Yang Tao24,Li Qiang25,Mu Yiming26,Zhao Jiajun27,Ning Guang12ORCID,Bi Yufang12,Wang Weiqing12,Xu Yu12ORCID,

Affiliation:

1. Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (S.W., M.L., J.L., R.Z., J.N., M.X., T.W., Z.Z., S.W., H.L., Y.C., G.N., Y.B., W.W., Y.X.).

2. Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the People’s Republic of China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (S.W., M.L., J.L., R.Z., J.N., M.X., T.W., Z.Z., S.W., H.L., Y.C., G.N., Y.B., W.W., Y.X.).

3. The First Hospital of Lanzhou University, China (X.T.).

4. The First Hospital of Jilin University, Changchun, China (G.W.).

5. Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, China (J.N.).

6. Qilu Hospital of Shandong University, Jinan, China (L.C.).

7. Jiangxi People’s Hospital, Nanchang, China (Y.H.).

8. The First Affiliated Hospital of Zhengzhou University, China (G.Q.).

9. Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (L.Y.).

10. The Affiliated Hospital of Southwest Medical University, Luzhou, China (Q.W.).

11. Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (L.C.).

12. Affiliated Hospital of Guiyang Medical College, China (L.S.).

13. Zhejiang Provincial Center for Disease Control and Prevention, China (R.H.).

14. Xinhua Hospital Affiliated to Shanghai Jiao-Tong University School of Medicine, China (Q.S.).

15. Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (X.Y.).

16. The First Affiliated Hospital of Guangxi Medical University, Nanning, China (Y.Q., Z.L.).

17. Fujian Provincial Hospital, Fujian Medical University, Fuzhou, China (G.C.).

18. Dalian Municipal Central Hospital, China (Z.G.).

19. The First Affiliated Hospital of Wenzhou Medical University, China (F.S.).

20. Central Hospital of Shanghai Jiading District, China (Y.Z.).

21. Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing, China (C.L.).

22. The First Affiliated Hospital of Anhui Medical University, Hefei, China (Y.W.).

23. Karamay Municipal People’s Hospital, Xinjiang, China (S.W.).

24. The First Affiliated Hospital of Nanjing Medical University, China (T.Y.).

25. The Second Affiliated Hospital of Harbin Medical University, Harbin, China (Q.L.).

26. Chinese People’s Liberation Army General Hospital, Beijing, China (Y.M.).

27. Shandong Provincial Hospital affiliated to Shandong University, Jinan, China (J.Z.).

Abstract

Background: High blood pressure (BP) is highly prevalent in patients with chronic kidney disease. However, the thresholds to initiate BP-lowering treatment in this population are unclear. We aimed to examine the associations between BP levels and clinical outcomes and provide evidence on potential thresholds to initiate BP-lowering therapy in people with chronic kidney disease. Methods: This nationwide, multicenter, prospective cohort study included 12 523 chronic kidney disease participants without antihypertensive therapy in mainland China. Participants were followed up during 2011 to 2016 for cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, hospitalized or treated heart failure, and cardiovascular death) and renal events (≥20% decline in the estimated glomerular filtration rate, end-stage kidney disease, and renal death). Results: Overall, 652 cardiovascular events and 1268 renal events occurred during 43 970 person-years of follow-up. We observed a positive and linear relationship between systolic BP and risks of cardiovascular and renal events down to 90 mm Hg, as well as between diastolic BP and risks of renal events down to 50 mm Hg. A J-shaped trend was noted between diastolic BP and risks of cardiovascular events, but a linear relationship was revealed in participants <60 years ( P for interaction <0.001). A significant increase in the risk of cardiovascular and renal outcomes was observed at systolic BP ≥130 mm Hg (versus 90–119 mm Hg) and at diastolic BP ≥90 mm Hg (versus 50–69 mm Hg). Conclusions: In people with chronic kidney disease, a higher systolic BP/diastolic BP level (≥130/90 mm Hg) is significantly associated with a greater risk of cardiovascular and renal events, indicating potential thresholds to initiate BP-lowering treatment.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Internal Medicine

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3